Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
Top Cited Papers
- 20 February 2006
- journal article
- hematologic malignancies
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (6) , 945-952
- https://doi.org/10.1200/jco.2005.04.2465
Abstract
Purpose: To describe the clinical, radiologic, and pathologic features and risk factors for osteonecrosis of the jaw (ONJ) in multiple myeloma (MM) patients. Patients and Methods: A retrospective review of 90 MM patients who had dental assessments, including 22 patients with ONJ. There were 62 men; the median age was 61 years in ONJ patients and 58 years among the rest. Prior MM therapy included thalidomide (n = 67) and stem-cell transplantation (n = 72). Bisphosphonate therapy included zoledronate (n = 34) or pamidronate (n = 17) and pamidronate followed by zoledronate (n = 33). Twenty-seven patients had recent dental extraction, including 12 patients in the ONJ group. Median time from MM diagnosis to ONJ was 8.4 years for the whole group. Results: Patients usually presented with pain. ONJ occurred posterior to the cuspids (n = 20) mostly in the mandible. Debridement and sequestrectomy with primary closure were performed in 14 patients; of these, four patients had major infections and four patients had recurrent ONJ. Bone histology revealed necrosis and osteomyelitis. Microbiology showed actinomycetes (n = 7) and mixed bacteria (n = 9). More than a third of ONJ patients also suffered from long bone fractures (n = 4) and/or avascular necrosis of the hip (n = 4). The variables predictive of developing ONJ were dental extraction (P = .009), treatment with pamidronate/zoledronate (P = .009), longer follow-up time (P = .03), and older age at diagnosis of MM (P = .006). Conclusion: ONJ appears to be time-dependent with higher risk after long-term use of bisphosphonates in older MM patients often after dental extractions. No satisfactory therapy is currently available. Trials addressing the benefits/risks of continuing bisphosphonate therapy are needed.Keywords
This publication has 37 references indexed in Scilit:
- Myeloma bone diseaseBest Practice & Research Clinical Haematology, 2005
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Bisphosphonate‐associated osteonecrosis of mandibular and maxillary boneCancer, 2005
- Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 casesJournal of Oral Pathology & Medicine, 2005
- Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label studyRheumatology, 2005
- Ethnicity-Related Gastric Cancer SurvivalJournal of Clinical Oncology, 2003
- Modified Fibonacci SearchJournal of Clinical Oncology, 2003
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- The antitumor potential of bisphosphonatesSeminars in Oncology, 2002
- Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic AcidThe Journal of Pharmacology and Experimental Therapeutics, 2002